Comparative Pharmacology
Head-to-head clinical analysis: ARDUAN versus METOCURINE IODIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARDUAN versus METOCURINE IODIDE.
ARDUAN vs METOCURINE IODIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent; competitively blocks acetylcholine at nicotinic receptors at the motor end-plate.
Competitive nicotinic acetylcholine receptor antagonist at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
Initial IV bolus of 0.08 mg/kg followed by incremental doses of 0.01 mg/kg to maintain neuromuscular blockade
Initial dose 0.2 mg/kg IV; maintenance doses of 0.1-0.15 mg/kg IV as needed for neuromuscular blockade.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.9 hours); prolonged in renal impairment
Terminal elimination half-life: 3-5 hours in patients with normal renal function. Prolonged in renal impairment.
Primarily renal (60-70% unchanged drug); biliary/fecal (20-30%)
Renal: 85-90% unchanged; biliary/fecal: <5%.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker